Eurofins creates one of the largest dedicated testing sites of its kind in the UK
£4 million investment will allow the Biopharmaceutical Product Testing business to expand its finished product and raw materials testing and increase capacity to deal with higher volumes.
Eurofins Scientific (EUFI.PA) has opened a new pharmaceutical chemistry and microbiology facility in Livingston, Scotland, following a £4 million investment.
The 5800-m2 facility will become one of the largest dedicated testing sites of its kind in the UK and the Biopharmaceutical Product Testing (BPT) UK business plans to double employee numbers over the next 5 years.
The new facility will allow the BPT business to expand its finished product and raw materials testing and increase capacity to deal with higher volumes. A greater number of technical specialists will also be available to work on method development and validation.
GMP microbiology contract testing will also be a focus, alongside elemental impurity testing which has benefited from the purchase of new equipment to enhance the capability of inductively coupled plasma mass spectrometry (ICP-MS) testing, enabling the company to meet growing demand for this service.
Eurofins will also invest in more high-performance liquid chromatography (HPLC) equipment, increasing its capacity by 40%.
Alison Clayton, General Manager, said the Livingston site would be one of the largest of all the Eurofins UK sites, which form part of a network of laboratories that work together across the UK, Ireland and Europe.
“The large investment in the facility will position the company in the best place to attract new customers thanks to greatly increased capacity, and is in line with Eurofins’ intent to attract significant future growth and development opportunities.
Eurofins BPT UK business will move from its current site in Newbridge, Edinburgh. The Livingston facility will also house new laboratories for Eurofins’ water testing business.
The investment follows Eurofins’ acquisition of Exova’s pharmaceutical, food and water testing business in the UK & Ireland in July 2016, and the subsequent purchase of ILS’s pharmaceutical business in October 2016.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance